NO20025849L - Fremgangsmåter og sammensetninger for anvendelse av sulodeksid for behandling av diabetisk nefropati - Google Patents

Fremgangsmåter og sammensetninger for anvendelse av sulodeksid for behandling av diabetisk nefropati

Info

Publication number
NO20025849L
NO20025849L NO20025849A NO20025849A NO20025849L NO 20025849 L NO20025849 L NO 20025849L NO 20025849 A NO20025849 A NO 20025849A NO 20025849 A NO20025849 A NO 20025849A NO 20025849 L NO20025849 L NO 20025849L
Authority
NO
Norway
Prior art keywords
diabetic nephropathy
sulodexide
treatment
methods
compositions
Prior art date
Application number
NO20025849A
Other languages
English (en)
Other versions
NO20025849D0 (no
Inventor
Ernesto Palazzini
Giovanni Gambaro
Original Assignee
Alfa Wassermann Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Inc filed Critical Alfa Wassermann Inc
Publication of NO20025849D0 publication Critical patent/NO20025849D0/no
Publication of NO20025849L publication Critical patent/NO20025849L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20025849A 2000-06-07 2002-12-05 Fremgangsmåter og sammensetninger for anvendelse av sulodeksid for behandling av diabetisk nefropati NO20025849L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20990700P 2000-06-07 2000-06-07
PCT/US2001/018411 WO2001093850A2 (en) 2000-06-07 2001-06-06 Methods and compositions using sulodexide for the treatment of diabetic nephropathy

Publications (2)

Publication Number Publication Date
NO20025849D0 NO20025849D0 (no) 2002-12-05
NO20025849L true NO20025849L (no) 2002-12-05

Family

ID=22780806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025849A NO20025849L (no) 2000-06-07 2002-12-05 Fremgangsmåter og sammensetninger for anvendelse av sulodeksid for behandling av diabetisk nefropati

Country Status (21)

Country Link
US (2) US7259152B2 (no)
EP (1) EP1292315B1 (no)
JP (1) JP2003535129A (no)
KR (1) KR100815287B1 (no)
AT (1) ATE409042T1 (no)
AU (2) AU6538801A (no)
BR (1) BR0111464A (no)
CA (1) CA2411243A1 (no)
CY (1) CY1108595T1 (no)
DE (1) DE60135911D1 (no)
DK (1) DK1292315T3 (no)
ES (1) ES2309070T3 (no)
HU (1) HUP0301408A2 (no)
IL (2) IL153074A0 (no)
MX (1) MXPA02011708A (no)
NO (1) NO20025849L (no)
NZ (1) NZ522963A (no)
PL (1) PL201658B1 (no)
PT (1) PT1292315E (no)
RU (1) RU2003100081A (no)
WO (1) WO2001093850A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011514A (es) * 2001-06-12 2004-10-28 Keryx Biopharmaceuticals Inc Metodos que utilizan glucosaminoglicanos para tratamiento de nefropatia.
JP2008540448A (ja) * 2005-05-05 2008-11-20 ケリク ビオファルマセウチカルス インコーポレーテッド 糖尿病性腎症の治療において、スロデキシド及び血圧低下薬を用いた併用療法
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
WO2008078176A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
FR3071283B1 (fr) * 2017-09-21 2022-07-29 Fineheart Pompe cardiaque equipee d'une turbine a pales internes

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2426586A1 (de) 1973-06-14 1975-01-09 Opocrin Srl Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IT1163772B (it) 1983-07-13 1987-04-08 Baldacci Lab Spa Oligosaccaridi eterogenei complessabili ed alfa-idosani ad attivita' terapeutica, procedimento per la loro preparazione e relative composizioni farmaceutiche
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5413645A (en) 1986-04-25 1995-05-09 Weirton Steel Corporation Light-cage composite-coated flat-rolled steel manufacture and product
US5672334A (en) 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
IT1234508B (it) 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5272261A (en) 1989-01-11 1993-12-21 Merrell Dow Pharmaceuticals Inc. Preparation of sulfated polysaccharide fractions
IT1234826B (it) 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5464942A (en) 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
US5073643A (en) 1990-08-30 1991-12-17 Polyset Corporation High yield synthesis of hydroxyl-containing cationic photoinitiators
IT1242604B (it) 1990-11-13 1994-05-16 Alfa Wassermann Spa Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazione e formulazioni farmaceutiche che li contengono.
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
IT1260136B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonicosostituito con radicali nucleofili in posizione 3
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1264101B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1264102B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali
IT1270846B (it) 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
US5585361A (en) 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
IT1299969B1 (it) 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
WO1999062535A2 (en) 1998-06-01 1999-12-09 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases

Also Published As

Publication number Publication date
WO2001093850B1 (en) 2003-02-20
CY1108595T1 (el) 2014-04-09
EP1292315A2 (en) 2003-03-19
EP1292315B1 (en) 2008-09-24
NZ522963A (en) 2004-11-26
AU6538801A (en) 2001-12-17
IL153074A0 (en) 2003-06-24
NO20025849D0 (no) 2002-12-05
WO2001093850A3 (en) 2002-08-22
AU2001265388B2 (en) 2006-12-14
CA2411243A1 (en) 2001-12-13
BR0111464A (pt) 2003-05-06
RU2003100081A (ru) 2004-07-20
US20020065233A1 (en) 2002-05-30
DK1292315T3 (da) 2008-11-17
IL153074A (en) 2008-07-08
PT1292315E (pt) 2008-10-16
US7259152B2 (en) 2007-08-21
MXPA02011708A (es) 2004-05-17
US20080045476A1 (en) 2008-02-21
ATE409042T1 (de) 2008-10-15
HUP0301408A2 (hu) 2003-11-28
PL201658B1 (pl) 2009-04-30
ES2309070T3 (es) 2008-12-16
WO2001093850A2 (en) 2001-12-13
KR20030031493A (ko) 2003-04-21
KR100815287B1 (ko) 2008-03-19
DE60135911D1 (de) 2008-11-06
PL359346A1 (en) 2004-08-23
JP2003535129A (ja) 2003-11-25

Similar Documents

Publication Publication Date Title
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
NO20003051L (no) Metode for administrering av AspB28-humant insulin
WO2007066149A3 (en) Topical pharmaceutical compositions
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
Kois New paradigms for anterior tooth preparation. Rationale and technique.
DE60115842D1 (de) Ventilanordnung
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
SE0001899D0 (sv) New compounds
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
MY120279A (en) Use of a celecoxib composition for fast pain relief
EE04175B1 (et) Meetod topiramaadi farmatseutilise kompositsioonivalmistamiseks, farmatseutiline kompositsioon ning topiramaadi kasutamine diabeedi raviks ette nähtud ravimi valmistamiseks
DK1409006T3 (da) Monodispergerede blandinger og fremgangsmåder til behandling af diabetes
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
ITFI20030058A1 (it) Formulazioni farmaceutiche contenenti tiazolidinedioni
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
NO20025849D0 (no) Fremgangsmåter og sammensetninger for anvendelse av sulodeksid for behandling av diabetisk nefropati
DK1660115T3 (da) Farmaceutisk kombination af G-CSF og PLGF anvendelig til blodstamceller
DK1289534T3 (da) Apoptotiske enheder til anvendelse ved behandling af T-cellemedierede og inflammatoriske lidelser
DK1643999T3 (da) Pyridoxamin til anvendelse ved behandlingen af diabetisk nefropati ved type 2-diabetes
BR0306798A (pt) Uso de melagatran ou de um derivado farmaceuticamente aceitável deste, métodos de tratamento de diabetes mellitus tipo i, de transplante de células de enxertamento de ilhotas de langerhans, para melhorar a independência de insulina em pacientes com diabetes mellitus tipo i, e de tratamento de reação inflamatória mediada pelo sangue instantânea, formulação farmacêutica para uso no tratamento de diabetes mellitus tipo i, kit de partes, e, método de fabricação de um kit de partes.
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
DE50005714D1 (de) Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application